HIV-Associated Lipodystrophy Syndrome

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE

Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone

Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy

MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)

Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients

Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients

Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients